Hyperglycaemia-induced activation of the reninangiotensin system (RAS) has been observed in normal and diabetic humans. Our main objective was to determine whether the mechanism involved a physical or metabolic effect of glucose. First, Sprague-Dawley rats of the CD strain were given sequential intravenous (i.v.) doses of 0.01, 0.1, 1.0, and 3.0 mg/kg candesartan 30 minutes apart, in the presence of a continuous i.v. infusion of dextrose 20% in water (D20W). The 0.1 mg/kg dose produced a maximal renal blood flow (RBF) response and was used thereafter. Another set of animals then received an infusion of either normal saline (NS), dextrose 5% in water (D5W) or dextrose 20% in water (D20W) for 2 hours, followed by candesartan 0.
Introduction
Sustained interest in dissecting the pathophysiology of diabetic nephropathy has led to a focus on renal haemodynamics. One factor that has fuelled this interest is the unequivocal benefit derived from angiotensin-converting enzyme (ACE) inhibition in diabetic nephropathy, despite an inconsistent relationship to the apparent state of the reninangiotensin system (RAS). For instance, in a study on Type 2 diabetic patients, baseline plasma renin activity (PRA) was reduced in the diabetic subjects, yet the renal vascular response to an angiotensin antagonist was substantially greater than normal, suggesting activation of the intrarenal RAS which was not reflected in plasma levels. 1 Thus, we are in search of factors leading to RAS activation in diabetes. Hyperglycaemia is a logical candidate. [2] [3] [4] Hyperglycaemia-induced activation of the intrarenal RAS has been shown in Type 1 diabetics and healthy subjects alike when renal plasma flow (RPF) was measured after an ACE inhibitor or an angiotensin II (Ang II) antagonist was given to block the RAS. [3] [4] [5] However, the mechanism underlying this phenomenon of glucose-mediated RAS activation is largely unknown. Are these changes a function of the osmotic effects of hyperglycaemia, for example, or of intracellular utilisation of glucose in particular? To answer this question, we laid out the following objectives.
Our first goal was to develop an animal model of hyperglycaemia leading to angiotensin-dependent renal vasoconstriction. To this end, we used the CD strain of Sprague-Dawley rats to determine whether hyperglycaemia would enhance the renal blood flow (RBF) response to an Ang II antagonist, candesartan. To achieve this, we had to identify the optimal candesartan dose. The second goal, the major objective of this study, was to determine whether glucose induced this change because of its metabolic effects, or as a physical consequence of elevation of blood sugar levels. For this, we compared the response to glucose infusion with the response to an infusion of a comparable dose of 2deoxyglucose (2DG). A glucose analogue, 2DG inhibits glycolysis through competitive antagonism of the enzyme hexokinase. 6 It thus causes intracellular glucose deprivation in various tissues, a decrease in insulin secretion, and an epinephrineinduced increase in extracellular glucose concentration. [7] [8] [9] By uncoupling extracellular glucose loading from intracellular glucose utilisation, it is possible to determine whether a response induced by hyperglycaemia is due to blood glucose levels per se or to an intracellular metabolic process. PE 250 tubing (Becton-Dickinson) was used to cannulate the trachea. The left jugular vein was cannulated with a triaxial catheter, consisting of three PE 10 catheters sheathed within a tefloncoated paediatric catheter and sealed with adhesive compound. The free end of each catheter was flared over an alcohol lamp to form a leak-proof seal within a luer adapter, and attached to a threeway stopcock. Each catheter was pre-flushed with sterile 0.9% saline, containing 0.6% heparin.
The left carotid artery was cannulated, using a length of PE 50 tubing connected to a 23-gauge luer stub adapter and a three-way stopcock. This catheter was also pre-flushed with saline/heparin and slightly bevelled at its tip. Animals remained anaesthetised throughout the experiment with sodium pentobarbital (50 mg/ml), infused at a constant rate of 5 mg/kg/hour. Blood pressure (BP) was measured using a P23 ID Gould BP transducer connected to a Grass Instruments Polygraph recorder.
The left renal artery was isolated via a left flank incision. An electromagnetic flow probe attached to a flowmeter (Caroline Medical Electronics, King, NC) was applied to the renal artery. RBF (ml/minute/g kidney) was recorded on the aforementioned Grass Instruments Polygraph recorder.
After a 20-minute equilibration period, basal arterial blood glucose levels (mg/dl) were measured using a glucometer (Accu-Check Advantage, Boehringer-Mannheim). Basal haematocrit (%) was also determined (Red-Tips, Fisher Scientific; Seal-ease, Clay Adams, International Microcapillary Reader, IEC).
Dose response
The first step was to ascertain whether candesartan induced a renal vasodilator response during glucose infusion and to determine the candesartan dose producing the maximal renal blood flow response during hyperglycaemia. Nineteen CD rats received an intravenous (i.v.) infusion of dextrose 20% in water (D20W), at a rate of 6.18 ml/hour. After 2 hours with the D20W infusion still continuing, i.v. candesartan was given at cumulative doses of 0.01, 0.1, 1.0, and 3.0 mg/kg, 30 minutes apart, with continuous monitoring of RBF and BP. The peak RBF and BP nadir recorded within each 30-minute period were considered to be the maximal response to that candesartan dose. In these CD rats given incremental doses of candesartan, the 0.1 mg/kg dose produced a maximal RBF response and was used thereafter.
Hyperglycaemia vs. euglycaemia
To determine whether elevated blood glucose levels potentiated the RBF response to ACE inhibition, CD rats were randomised to receive an infusion of either dextrose 5% in water (D5W, n=8), dextrose 20% in water (D20W, n=29), or normal saline (NS, n=17), at an initial rate of 6.18 ml/hour i.v. The rates were adjusted as described below. After 2 hours of equilibration and with the infusates continuing, candesartan 0.1 mg/kg i.v. was given. The RBF response was defined as the peak RBF attained after candesartan administra-tion minus the baseline RBF (i.e. the RBF at the end of 2 hours of D5W, D20W, or NS infusion).
Glucose vs. 2-deoxyglucose
To test whether the effect of hyperglycaemia was due to the extracellular glucose concentration or the intracellular utilisation of glucose, the CD rats in the D20W group (n=29) were compared with rats infused with 2DG (n=9) 50 mg/ml i.v. at an initial rate of 6.18 ml/hour. The rates were adjusted as described below. At the end of 2 hours, and with the infusates still continuing, candesartan 0.1 mg/kg was given i.v. As discussed earlier, 2DG is expected to raise blood glucose levels by blocking glycolysis, thus uncoupling extracellular glucose loading from intracellular glucose metabolism. The RBF response was defined as the peak RBF attained after candesartan administration minus the baseline RBF (i.e. the RBF after 2 hours of D20W or 2DG infusion).
Monitoring
RBF and BP were monitored continuously. The 2hour periods of infusion of NS, D5W, D20W, and 2DG before candesartan were considered as equilibration periods. RBF and BP at the end of these 2-hour equilibration periods were considered the baseline values. After candesartan administration, RBF and BP were monitored continuously for 30 minutes and the peak responses noted. Blood glucose levels were measured every 30 minutes and the D5W, D20W, and 2DG infusions were adjusted to maintain blood glucose levels of 1.5 times the baseline. Urine was collected externally into conical 1.5 ml Eppendorf tubes for immediate urinary glucose determinations (ChemStix, Fisher Scientific). Haematocrit was measured at baseline and at the end of the experiment.
Animal care
The animals used were maintained in accordance with the guidelines of the Committee 
Statistical analyses
Mean values were used, together with the standard error of the mean (SEM) as the index of dispersion. ANOVA was used for the dose-response relationships and the hyperglycaemia-euglycaemia comparison, with the Tukey test for multiple pairwise comparisons. Paired t-test or Wilcoxon signed rank test was used to compare baseline and peak RBF and BP. Mann-Whitney rank sum test or t-test was used to compare the blood glucose levels, RBF and BP of the D20W and 2DG groups.
Results

Dose response
In the CD rats given increasing doses of candesartan, the 0.1 mg/kg dose effected a maximal RBF response (0.87±0.30 ml/minute/g kidney, peak vs. baseline p=0.011; Table 1 ). There was a significant and different dose-response relationship for BP (p=0.042) with the greatest response at 3.0 mg/kg (Table 1) .
Hyperglycaemia vs. euglycaemia
Baseline RPF and BP were similar in all three groups (p=0.131 and p=0.918, respectively). A significant RBF response to candesartan was seen only with hyperglycaemia (D20W group; n=29; 6.64±0.59 to 7.46±0.67 ml/minute/g kidney; Table 2 ). There was no significant response in either the NS (n=17; p=0.216) or D5W (n=8; p=0.965) groups. Hyperglycaemia was achieved only in the D20W group (150.1±11.6 mg/dl) whereas the NS (78.6±7.7) and D5W (82.0±6.7) groups remained euglycaemic (NS vs. D5W, p=0.783). BP decreased significantly in all three groups after candesartan administration ( Table 2) .
Glucose vs. 2-deoxyglucose
Because hyperglycaemia was achieved only in the D20W group, this was the group compared with the rats that received 2DG (n=9). Baseline RBF for 2DG was 6.55±0.7 ml/minute/g kidney, which was comparable to the D20W group (p=0.818). After candesartan, RBF for 2DG was 6.51±0.7 ml/minute/g kidney. A significant RBF response to candesartan was seen only with D20W and not with 2DG (delta RBF: D20W 0.82±0.22 vs. 2DG -0.04±0.26, p=0.050; Figure 1A ).Blood glucose levels (D20W 150.11±11.6 vs. 2DG 152.3±15.9 mg/dl; p=0.764; Figure 1B ) and urine glucose levels (D20W 863.6±97.5 vs. 2DG 816.7±285.8 mg/dl; p=0.684) were similar in the two groups. The two groups also had comparable baseline BPs (D20W 111.3±3.9 vs. 2DG 113.0±4.6 mmHg;p=0.865) and BP responses after candesartan administration (D20W -18.5±2.8 mm Hg vs. 2DG -10.9±2.5 mmHg; p=0.149).
Haematocrit
There was no significant change in haematocrit compared with initial values in any of the groups (NS: p=0.698; D5W: p=0.077; D20W: p=0.448; 2DG: p=0.634, Table 3 ).
Discussion
We wanted to determine the mechanism by which hyperglycaemia causes activation of the RAS. To do this, we set two goals.
The first was to develop an animal model for addressing these issues. CD rats were used for this purpose. RBF showed a significant vasodilator response to candesartan in the presence of hyperglycaemia, compared with that during normoglycaemia. The infusion of D5W did not appreciably increase blood glucose levels: thus, the groups that may be used for comparison are NS and D20W. The enhanced response to an Ang II antagonist while on D20W suggests hyperglycaemia-induced activation of the RAS.
The next objective was to determine whether glucose exerted a renal haemodynamic effect because of intracellular glucose utilisation or because of extracellular glucose loading. If the latter were solely to explain the enhancement in RBF, then we would expect no difference in the effects of D20W and 2DG and could thus attribute the RBF change to osmotic pressure-mediated RAS activation. However, we observed a greater increase in RBF in the D20W group compared with the 2DG group, despite the similar BP responses, blood glucose and urine glucose levels in the two groups. This suggests that RAS activation is, at least in part, due to intracellular glucose metabolism and not merely a result of glucose-loading.
If glucose caused an activation of the RAS, why were the RBFs of the D20W and NS groups similar after 2 hours of infusion? Studies have shown variable effects of hyperglycaemia on renal haemodynamics. Baseline RBF was significantly lower during hyperglycaemia compared with euglycaemia, in a study in Type 1 diabetic human subjects. 10 Other studies have shown a decrease, 11 or no change, 12, 13 in renal plasma flow (RPF) with an increase in blood glucose levels in humans. Declines in blood flow in other organ systems have been demonstrated in animal models of hyperglycaemia. 14, 15 On the other PAPER 16, 17 alike. These studies vary in terms of glucose dose, duration of hyperglycaemia, and whether the subjects had diabetes or not. Such factors might account for the different results. PRA levels were not measured in our study. The amount of blood required to determine PRA at multiple time points would have rendered our results uninterpretable. On the other hand,blood loss (from the surgery and the glucose and haematocrit determinations) and the intravenous fluid infusions did not produce a significant effect on haematocrit values in any of the groups, indicating that there were no significant plasma shifts. This suggests that the animals were neither volume-expanded from the infusions, nor dehydrated from the effects of an osmotic load.
It is not possible to exclude other causes of RAS activation in our study. The effect of anaesthesia and the surgical manipulation might have already affected baseline RBF and the state of the RAS, as shown by many investigators. [18] [19] [20] If hyperglycaemia were not a contributor to RAS activation, however, one would expect the NS and D20W groups in the present study to have the same renal haemodynamic response to candesartan, since the two groups underwent identical procedures. By the same token, the D20W and 2DG groups should also have responded similarly. This was clearly not the case. Hyperglycaemia, most likely from an intracellular metabolic mechanism, caused RAS activation over and above any activation that could have arisen from surgery and anaesthesia. A shift in potassium levels resulting from changes in glucose load can also affect the state of RAS activation. However, since there was a RBF response to candesartan on D20W and not to 2DG, glucose seems to have an effect separate from hyperglycaemia alone.
Earlier research suggested that RAS activation may be a consequence of the physical effect of osmotic pressure. In a study of the renal haemodynamic response to contrast media, Caldicott et al. reported that hypertonicity of the agents elicited RAS activation and consequently vasoconstriction after an initial transient vasodilation phase. 21 They suggested a change in tubular osmolality or a change in osmotic potential across the tubular cell at the macula densa as possible mechanisms for the hypertonicity-induced RAS activation. Since there were differing renal responses to D20W and 2DG, two agents that cause the same degree of hyperglycaemia, the discrepancy must be explained by the intracellular metabolism of glucose, a process blocked by the glucose analogue, 2DG. Hence, the activation of RAS by glucose is most likely not dependent on its osmotic effects.
Although this study points to an intracellular action of glucose, it does not preclude the fact that there may be other substances mediating the effect of glucose on RAS activation. Insulin has been shown to cause renal vasodilation, 22, 23 and nitric oxide (NO) has been postulated as a mediator of diabetic hyperfiltration. 16 Insulin levels were not measured in this experiment, but it is known that 2DG does not increase insulin levels whereas D20W does. Furthermore, NO may account for some of the vasodilatory action of insulin. 24 Their roles in RAS activation in the presence of hyperglycaemia need to be investigated further.
In summary, we have developed an animal model to investigate the mechanism of hyperglycaemiainduced RAS activation. The mechanism involves a metabolic, rather than a physical, osmotic effect of glucose. These findings could further shed light on the pathogenesis of diabetes-induced renal injury. Table 3 Haematocrit values (%) at the beginning and end of the experiment for the normal saline (NS), dextrose 5% in water (D5W), dextrose 20% in water (D20W) and 2-deoxyglucose (2DG) groups. 
